SDGR vs. HRMY, GPCR, PTGX, EWTX, KURA, SUPN, TARO, SYRE, RCUS, and ARDX
Should you be buying Schrödinger stock or one of its competitors? The main competitors of Schrödinger include Harmony Biosciences (HRMY), Structure Therapeutics (GPCR), Protagonist Therapeutics (PTGX), Edgewise Therapeutics (EWTX), Kura Oncology (KURA), Supernus Pharmaceuticals (SUPN), Taro Pharmaceutical Industries (TARO), Spyre Therapeutics (SYRE), Arcus Biosciences (RCUS), and Ardelyx (ARDX). These companies are all part of the "pharmaceutical preparations" industry.
Schrödinger (NASDAQ:SDGR) and Harmony Biosciences (NASDAQ:HRMY) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, community ranking, dividends, profitability and media sentiment.
Harmony Biosciences has a net margin of 22.30% compared to Schrödinger's net margin of -75.94%. Harmony Biosciences' return on equity of 28.26% beat Schrödinger's return on equity.
Schrödinger received 7 more outperform votes than Harmony Biosciences when rated by MarketBeat users. However, 60.29% of users gave Harmony Biosciences an outperform vote while only 55.17% of users gave Schrödinger an outperform vote.
Harmony Biosciences has higher revenue and earnings than Schrödinger. Schrödinger is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.
79.1% of Schrödinger shares are held by institutional investors. Comparatively, 86.2% of Harmony Biosciences shares are held by institutional investors. 7.6% of Schrödinger shares are held by insiders. Comparatively, 30.8% of Harmony Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
In the previous week, Schrödinger had 1 more articles in the media than Harmony Biosciences. MarketBeat recorded 4 mentions for Schrödinger and 3 mentions for Harmony Biosciences. Harmony Biosciences' average media sentiment score of 1.12 beat Schrödinger's score of 0.44 indicating that Harmony Biosciences is being referred to more favorably in the news media.
Schrödinger has a beta of 1.58, indicating that its stock price is 58% more volatile than the S&P 500. Comparatively, Harmony Biosciences has a beta of 0.75, indicating that its stock price is 25% less volatile than the S&P 500.
Schrödinger presently has a consensus price target of $42.80, indicating a potential upside of 91.33%. Harmony Biosciences has a consensus price target of $40.63, indicating a potential upside of 39.56%. Given Schrödinger's stronger consensus rating and higher probable upside, equities analysts plainly believe Schrödinger is more favorable than Harmony Biosciences.
Summary
Harmony Biosciences beats Schrödinger on 11 of the 17 factors compared between the two stocks.
Get Schrödinger News Delivered to You Automatically
Sign up to receive the latest news and ratings for SDGR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SDGR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Schrödinger Competitors List
Related Companies and Tools
